12:00 AM
 | 
Apr 15, 2013
 |  BC Week In Review  |  Company News  |  Deals

LigoCyte Pharmaceuticals, Takeda deal

Takeda will acquire LigoCyte for $60 million up front, plus potential milestones. LigoCyte's lead product is a norovirus VLP intranasal vaccine in Phase I/II testing to prevent...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >